| 1. Executive Summary |
| 2. Global EGFR Expressing Solid Tumors Treatment Market Introduction |
| 2.1. Global EGFR Expressing Solid Tumors Treatment Market - Taxonomy |
| 2.2. Global EGFR Expressing Solid Tumors Treatment Market - Definitions |
| 2.2.1. Therapeutic Agent |
| 2.2.2. Route of Administration |
| 2.2.3. Region |
| 3. Global EGFR Expressing Solid Tumors Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Key Developments |
| 4. Global EGFR Expressing Solid Tumors Treatment Market By Therapeutic Agent, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 4.1. First-Generation EGFR-TKIs |
| 4.1.1. Gefitinib |
| 4.1.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.1.3. Market Opportunity Analysis |
| 4.1.2. Erlotinib |
| 4.1.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.2.3. Market Opportunity Analysis |
| 4.1.3. Icotinib |
| 4.1.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.3.3. Market Opportunity Analysis |
| 4.1.4. Lapatinib |
| 4.1.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.1.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.4.3. Market Opportunity Analysis |
| 4.1.5. Vandetanib |
| 4.1.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.1.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.5.3. Market Opportunity Analysis |
| 4.2. Second-Generation EGFR-TKIs |
| 4.2.1. Afatinib |
| 4.2.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.2.1.3. Market Opportunity Analysis |
| 4.2.2. Brigatinib |
| 4.2.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.2.2.3. Market Opportunity Analysis |
| 4.2.3. Dacomitinib |
| 4.2.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.2.3.3. Market Opportunity Analysis |
| 4.2.4. Neratinib |
| 4.2.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.2.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.2.4.3. Market Opportunity Analysis |
| 4.2.5. Others |
| 4.2.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.2.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.2.5.3. Market Opportunity Analysis |
| 4.3. Third-Generation EGFR-TKIs |
| 4.3.1. Osimertinib |
| 4.3.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.3.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.3.1.3. Market Opportunity Analysis |
| 4.3.2. Olmutinib |
| 4.3.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.3.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3.2.3. Market Opportunity Analysis |
| 4.3.3. Rociletinib |
| 4.3.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.3.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3.3.3. Market Opportunity Analysis |
| 4.3.4. Naquotinib |
| 4.3.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.3.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3.4.3. Market Opportunity Analysis |
| 4.3.5. Others |
| 4.3.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.3.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3.5.3. Market Opportunity Analysis |
| 4.4. Fourth-Generation EGFR-TKIs |
| 4.4.1. EAI001 |
| 4.4.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.4.1.3. Market Opportunity Analysis |
| 4.4.2. EAI045 |
| 4.4.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.4.2.3. Market Opportunity Analysis |
| 4.5. Monoclonal Antibodies |
| 4.5.1. Cetuximab |
| 4.5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.5.1.3. Market Opportunity Analysis |
| 4.5.2. Panitumumab |
| 4.5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.5.2.3. Market Opportunity Analysis |
| 4.5.3. Others |
| 4.5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.5.3.3. Market Opportunity Analysis |
| 5. Global EGFR Expressing Solid Tumors Treatment Market By Route of Administration, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 5.1. Oral |
| 5 1 1 Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Parenteral |
| 5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6. Global EGFR Expressing Solid Tumors Treatment Market By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 6.1. North America |
| 6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Europe |
| 6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Asia Pacific |
| 6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Latin America |
| 6.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. MEA |
| 6.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Global EGFR Expressing Solid Tumors Treatment Market - Opportunity Analysis Index, By Route of Administration, Therapeutic Agent, , , , , , and Region, 2024-2030 |
| 7. North America EGFR Expressing Solid Tumors Treatment Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 7.1. Therapeutic Agent Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 7.1.1. First-Generation EGFR-TKIs |
| 7.1.1.1. Gefitinib |
| 7.1.1.2. Erlotinib |
| 7.1.1.3. Icotinib |
| 7.1.1.4. Lapatinib |
| 7.1.1.5. Vandetanib |
| 7.1.2. Second-Generation EGFR-TKIs |
| 7.1.2.1. Afatinib |
| 7.1.2.2. Brigatinib |
| 7.1.2.3. Dacomitinib |
| 7.1.2.4. Neratinib |
| 7.1.2.5. Others |
| 7.1.3. Third-Generation EGFR-TKIs |
| 7.1.3.1. Osimertinib |
| 7.1.3.2. Olmutinib |
| 7.1.3.3. Rociletinib |
| 7.1.3.4. Naquotinib |
| 7.1.3.5. Others |
| 7.1.4. Fourth-Generation EGFR-TKIs |
| 7.1.4.1. EAI001 |
| 7.1.4.2. EAI045 |
| 7.1.5. Monoclonal Antibodies |
| 7.1.5.1. Cetuximab |
| 7.1.5.2. Panitumumab |
| 7.1.5.3. Others |
| 7.2. Route of Administration Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 7.2.1. Oral |
| 7.2.2. Parenteral |
| 7.3. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 7.3.1. USA |
| 7.3.2. Canada |
| 8. Europe EGFR Expressing Solid Tumors Treatment Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 8.1. Therapeutic Agent Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. First-Generation EGFR-TKIs |
| 8.1.1.1. Gefitinib |
| 8.1.1.2. Erlotinib |
| 8.1.1.3. Icotinib |
| 8.1.1.4. Lapatinib |
| 8.1.1.5. Vandetanib |
| 8.1.2. Second-Generation EGFR-TKIs |
| 8.1.2.1. Afatinib |
| 8.1.2.2. Brigatinib |
| 8.1.2.3. Dacomitinib |
| 8.1.2.4. Neratinib |
| 8.1.2.5. Others |
| 8.1.3. Third-Generation EGFR-TKIs |
| 8.1.3.1. Osimertinib |
| 8.1.3.2. Olmutinib |
| 8.1.3.3. Rociletinib |
| 8.1.3.4. Naquotinib |
| 8.1.3.5. Others |
| 8.1.4. Fourth-Generation EGFR-TKIs |
| 8.1.4.1. EAI001 |
| 8.1.4.2. EAI045 |
| 8.1.5. Monoclonal Antibodies |
| 8.1.5.1. Cetuximab |
| 8.1.5.2. Panitumumab |
| 8.1.5.3. Others |
| 8.2. Route of Administration Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Oral |
| 8.2.2. Parenteral |
| 8.3. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1. Germany |
| 8.3.2. France |
| 8.3.3. Italy |
| 8.3.4. Spain |
| 8.3.5. UK |
| 8.3.6. Rest of Europe |
| 9. Asia Pacific EGFR Expressing Solid Tumors Treatment Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 9.1. Therapeutic Agent Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. First-Generation EGFR-TKIs |
| 9.1.1.1. Gefitinib |
| 9.1.1.2. Erlotinib |
| 9.1.1.3. Icotinib |
| 9.1.1.4. Lapatinib |
| 9.1.1.5. Vandetanib |
| 9.1.2. Second-Generation EGFR-TKIs |
| 9.1.2.1. Afatinib |
| 9.1.2.2. Brigatinib |
| 9.1.2.3. Dacomitinib |
| 9.1.2.4. Neratinib |
| 9.1.2.5. Others |
| 9.1.3. Third-Generation EGFR-TKIs |
| 9.1.3.1. Osimertinib |
| 9.1.3.2. Olmutinib |
| 9.1.3.3. Rociletinib |
| 9.1.3.4. Naquotinib |
| 9.1.3.5. Others |
| 9.1.4. Fourth-Generation EGFR-TKIs |
| 9.1.4.1. EAI001 |
| 9.1.4.2. EAI045 |
| 9.1.5. Monoclonal Antibodies |
| 9.1.5.1. Cetuximab |
| 9.1.5.2. Panitumumab |
| 9.1.5.3. Others |
| 9.2. Route of Administration Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Oral |
| 9.2.2. Parenteral |
| 9.3. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. China |
| 9.3.2. Japan |
| 9.3.3. South Korea |
| 9.3.4. India |
| 9.3.5. Rest of APAC |
| 10. Latin America EGFR Expressing Solid Tumors Treatment Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 10.1. Therapeutic Agent Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. First-Generation EGFR-TKIs |
| 10.1.1.1. Gefitinib |
| 10.1.1.2. Erlotinib |
| 10.1.1.3. Icotinib |
| 10.1.1.4. Lapatinib |
| 10.1.1.5. Vandetanib |
| 10.1.2. Second-Generation EGFR-TKIs |
| 10.1.2.1. Afatinib |
| 10.1.2.2. Brigatinib |
| 10.1.2.3. Dacomitinib |
| 10.1.2.4. Neratinib |
| 10.1.2.5. Others |
| 10.1.3. Third-Generation EGFR-TKIs |
| 10.1.3.1. Osimertinib |
| 10.1.3.2. Olmutinib |
| 10.1.3.3. Rociletinib |
| 10.1.3.4. Naquotinib |
| 10.1.3.5. Others |
| 10.1.4. Fourth-Generation EGFR-TKIs |
| 10.1.4.1. EAI001 |
| 10.1.4.2. EAI045 |
| 10.1.5. Monoclonal Antibodies |
| 10.1.5.1. Cetuximab |
| 10.1.5.2. Panitumumab |
| 10.1.5.3. Others |
| 10.2. Route of Administration Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Oral |
| 10.2.2. Parenteral |
| 10.3. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Brazil |
| 10.3.2. Mexico |
| 10.3.3. Argentina |
| 10.3.4. Rest of Latin America |
| 11. MEA EGFR Expressing Solid Tumors Treatment Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 11.1. Therapeutic Agent Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. First-Generation EGFR-TKIs |
| 11.1.1.1. Gefitinib |
| 11.1.1.2. Erlotinib |
| 11.1.1.3. Icotinib |
| 11.1.1.4. Lapatinib |
| 11.1.1.5. Vandetanib |
| 11.1.2. Second-Generation EGFR-TKIs |
| 11.1.2.1. Afatinib |
| 11.1.2.2. Brigatinib |
| 11.1.2.3. Dacomitinib |
| 11.1.2.4. Neratinib |
| 11.1.2.5. Others |
| 11.1.3. Third-Generation EGFR-TKIs |
| 11.1.3.1. Osimertinib |
| 11.1.3.2. Olmutinib |
| 11.1.3.3. Rociletinib |
| 11.1.3.4. Naquotinib |
| 11.1.3.5. Others |
| 11.1.4. Fourth-Generation EGFR-TKIs |
| 11.1.4.1. EAI001 |
| 11.1.4.2. EAI045 |
| 11.1.5. Monoclonal Antibodies |
| 11.1.5.1. Cetuximab |
| 11.1.5.2. Panitumumab |
| 11.1.5.3. Others |
| 11.2. Route of Administration Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Oral |
| 11.2.2. Parenteral |
| 11.3. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. GCC Countries |
| 11.3.2. South Africa |
| 11.3.3. Rest of MEA |
| 12. Competition Landscape |
| 12.1. Strategic Dashboard of Top Market Players |
| 12.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 12.2.1. Intelicure Lifesciences |
| 12.2.2. AstraZeneca |
| 12.2.3. Teva Pharmaceuticals |
| 12.2.4. Genentech, Inc |
| 12.2.5. Betta Pharmaceuticals Co., Ltd |
| 12.2.6. Dr. Reddy’s Laboratories |
| 12.2.7. GlaxoSmithKline (GSK) |
| 12.2.8. Sanofi |
| 12.2.9. Boehringer Ingelheim Pharmaceuticals, Inc |
| 12.2.10. Takeda Pharmaceutical Company Limited |
| 12.2.11. Pfizer Inc |
| 12.2.12. Puma Biotechnology, Inc |
| 13. Research Methodology |
| 14. Key Assumptions and Acronyms |
